---
{"dg-publish":true,"permalink":"/general-notes/summary-of-participant-characteristics/"}
---



## Summary

| Study            | Total Sample | Autism Group                        | Typically Developing Group | Age Range                                      | Gender Distribution                            | Clinical Assessments                           | Exclusion Criteria                                |
|-----------------|--------------|-------------------------------------|----------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|--------------------------------------------------|
| [[Literature_review/forbes2025\|forbes2025]]    | 405          | 66 ASD, 146 ASD+ADHD               | 129 NT                     | 4–18 years (Mean: 9.64 ± 3.20)                 | N/A                                            | ADOS-2, CPRS, SRS-2, WISC-V, VABS-3             | ADHD medication stopped 48-72 hours before testing |
| [[Literature_review/ganai2025\|ganai2025]]    | 61           | 32 ASD                             | 29 TD                      | Mean ASD: 5.97, Mean TD: 4.86                 | N/A                                            | ISAA, VABS-3                                   | Neurological/genetic conditions, preterm birth, medication use |
| [[Literature_review/perochon2023a\|perochon2023a]] | 475          | 49 ASD                             | 328 TD                     | 17–36 months                                   | 269 boys, 206 girls                            | N/A                                            | Illness/distress preventing participation        |
| [[Literature_review/chetcuti2024\|chetcuti2024]]  | 54           | Infants referred for ASD signs      | N/A                        | 9–14 months                                    | N/A                                            | AOSI, MSEL, VABS-II, IBQ-R                     | N/A                                              |
| [[Literature_review/chien2023\|chien2023]]  | 48           | 18 ASD                             | 30 TD                      | 4–13 years                                     | 10 males, 8 females (ASD); 19 males, 11 females (TD) | DSM-5, ICD-10                                 | Major neuropsychiatric disorders                 |
| [[Literature_review/zhang2025a\|zhang2025a]] | 37           | 23 ASD                             | 14 TD                      | Mean ASD: 6.05, Mean TD: 6.96                 | 4 girls (ASD), 3 girls (TD)                    | N/A                                            | N/A                                              |
| [[Literature_review/zaharia2024\|zaharia2024]]   | 94           | 63 ASD (23 High Severity, 40 Low-Moderate) | 31 TD              | 20–83 months                                   | 73 males, 21 females                           | ADOS-2                                         | Poor eye-tracking data (<50% fixation time)      |
| [[Literature_review/journal2024\|journal2024]]   | 171          | 103 ASD                            | 68 TD                      | 18–60 months                                   | 18 females (ASD), 28 females (TD)              | ESCS                                           | Severe cognitive impairment                      |
| [[Literature_review/kojovic2024\|kojovic2024]]  | 217          | 166 ASD                            | 51 TD                      | 1.7–6.9 years                                  | Only males                                     | ADOS-2                                         | Severe cognitive impairment                      |
| [[Literature_review/keehn2024\|keehn2024]]    | 146          | 102 ASD                            | 44 TD                      | 14–48 months (Mean: 2.6 ± 0.6)                 | 71% male, 29% female                           | ADOS-2                                         | Severe cognitive impairment, incomplete eye-tracking data |
| [[Literature_review/ricou2024\|ricou2024]]  | 259          | 109 ASD                            | 150 TD                     | 3–34 years (ASD: 13.03 ± 7.90, TD: 13.05 ± 7.39) | 93 males, 16 females (ASD); 84 males, 66 females (TD) | CARS, DQ                                       | Neurological disorders, vision impairments       |
